Objective: S.T.A.R.T. (Study of Travatan as Replacement Therapy) is an open label, multi-center, prospective, four week trial to evaluate the IOP lowering efficacy of Travatan (travoprost ophthalmic solution, 0.004%) ...Objective: S.T.A.R.T. (Study of Travatan as Replacement Therapy) is an open label, multi-center, prospective, four week trial to evaluate the IOP lowering efficacy of Travatan (travoprost ophthalmic solution, 0.004%) in patients requiring prostaglandin analogue therapy. This analysis reports on patients that were展开更多
Objective: S.T.A.R.T. (Study of Travatan as Replacement Therapy) is an open label, multi-center, prospective, four week trial to evaluate the IOP lowering efficacy of Travatan (travoprost ophthalmic solution, 0.004%) ...Objective: S.T.A.R.T. (Study of Travatan as Replacement Therapy) is an open label, multi-center, prospective, four week trial to evaluate the IOP lowering efficacy of Travatan (travoprost ophthalmic solution, 0.004%) in patients requiring prostaglandin analogue therapy. This analysis reports on patients that were展开更多
Several recent clinical studies (AGIS, CIGTS, OHTS, and EMGT) have shown the importance of lowering intraocular pressure (IOP) in slowing the progression of glaucomatous optic neuropathy. Other clinical trials have sh...Several recent clinical studies (AGIS, CIGTS, OHTS, and EMGT) have shown the importance of lowering intraocular pressure (IOP) in slowing the progression of glaucomatous optic neuropathy. Other clinical trials have shown that reducing the diurnal fluctuation in IOP favors maintaining stable visual fields. Available prostaglandin analogues achieve IOP reductions展开更多
文摘Objective: S.T.A.R.T. (Study of Travatan as Replacement Therapy) is an open label, multi-center, prospective, four week trial to evaluate the IOP lowering efficacy of Travatan (travoprost ophthalmic solution, 0.004%) in patients requiring prostaglandin analogue therapy. This analysis reports on patients that were
文摘Objective: S.T.A.R.T. (Study of Travatan as Replacement Therapy) is an open label, multi-center, prospective, four week trial to evaluate the IOP lowering efficacy of Travatan (travoprost ophthalmic solution, 0.004%) in patients requiring prostaglandin analogue therapy. This analysis reports on patients that were
文摘Several recent clinical studies (AGIS, CIGTS, OHTS, and EMGT) have shown the importance of lowering intraocular pressure (IOP) in slowing the progression of glaucomatous optic neuropathy. Other clinical trials have shown that reducing the diurnal fluctuation in IOP favors maintaining stable visual fields. Available prostaglandin analogues achieve IOP reductions
